Obseva (NASDAQ:OBSV)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research note issued on Monday, MarketBeat.com reports. They presently have a $36.00 target price on the stock, down from their previous target price of $44.00.
A number of other research analysts also recently commented on the company. Wedbush restated a “buy” rating and set a $38.00 price objective on shares of Obseva in a research note on Thursday, October 31st. Credit Suisse Group cut Obseva from an “outperform” rating to a “neutral” rating and cut their target price for the company from $16.00 to $4.00 in a research note on Friday, November 8th. Royal Bank of Canada reissued a “buy” rating on shares of Obseva in a report on Sunday, August 11th. BidaskClub upgraded shares of Obseva from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 30th. Finally, Zacks Investment Research raised shares of Obseva from a “sell” rating to a “hold” rating in a report on Saturday, November 9th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $22.75.
Shares of NASDAQ OBSV opened at $4.52 on Monday. The stock has a market capitalization of $196.02 million, a P/E ratio of -2.37 and a beta of 0.59. The firm’s 50-day moving average price is $5.40 and its two-hundred day moving average price is $8.92. Obseva has a 52-week low of $2.37 and a 52-week high of $15.93. The company has a quick ratio of 3.65, a current ratio of 3.65 and a debt-to-equity ratio of 0.38.
A number of institutional investors and hedge funds have recently bought and sold shares of OBSV. Capital Investment Advisory Services LLC bought a new stake in Obseva during the 2nd quarter valued at $40,000. Renaissance Technologies LLC lifted its holdings in Obseva by 7.6% in the second quarter. Renaissance Technologies LLC now owns 79,600 shares of the company’s stock worth $900,000 after purchasing an additional 5,600 shares during the period. AXA lifted its holdings in Obseva by 7.8% in the second quarter. AXA now owns 500,313 shares of the company’s stock worth $5,659,000 after purchasing an additional 36,356 shares during the period. Morgan Stanley lifted its holdings in Obseva by 358.6% in the second quarter. Morgan Stanley now owns 3,100 shares of the company’s stock worth $35,000 after purchasing an additional 2,424 shares during the period. Finally, Cubist Systematic Strategies LLC grew its position in Obseva by 263.6% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,272 shares of the company’s stock valued at $37,000 after buying an additional 2,372 shares in the last quarter. Hedge funds and other institutional investors own 61.47% of the company’s stock.
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Read More: Cost of Capital Explained
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.